97055 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants Molecules with a "CD"-designation not provided for elsewhere
EXTRACELLULAR VESICLES OVEREXPRESSING FIBRONECTIN FRAGMENT PROTEIN, AND USE FOR DRUG DELIVERY THEREOF
#2CD33 TARGETED IMMUNOTHERAPIES
#3Tcd34 And Other Markers For Identification And Sorting Of Cells And For Use As In Vivo Tracking Assistant
#4GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD98HC
#5NOVEL CD200 FUSION PROTEINS
#6PLATFORMS, COMPOSITIONS, AND METHODS FOR THERAPEUTIC DELIVERY
#7Multispecific antigen binding proteins for tumor-targeting of NK cells and use thereof
#8USE OF ONCOLYTIC VIRUSES, ALONE OR IN COMBINATION WITH A CHECKPOINT INHIBITOR, FOR THE TREATMENT OF CANCER
#9METHOD FOR LOADING DIMERIC CD24 INTO HEK293 CELL EXTRACELLULAR VESICLES WITH ADAM10 GENE KNOCKED OUT
#10CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE
#11ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#12ANTI-HUMAN COMPLEMENT C5 ANTIBODY AND FUSION PROTEIN THEREOF
#13CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
#14APPROACHES TO DISCOVERING, ANALYZING, AND SYNTHESIZING COMPOUNDS THROUGH AUTOMATED IN SILICO EXPERIMENTATION
#15COMBINATION OF NY-ESO-1 SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS
#16BIOORTHOGONAL T CELL RECEPTOR MOLECULES AND METHODS OF MAKING AND USING THE SAME
#17CONSTRUCTION OF ENGINEERED EXTRACELLULAR VESICLE AND USE THEREOF
#18METHODS AND COMPOSITIONS FOR PROMOTING OPC DIFFERENTIATION AND REMYELINATION USING RECEPTOR ASSOCIATED PROTEIN (RAP)
#19COMPOSITIONS AND METHODS FOR ARTIFICIAL PROTOSPACER ADJACENT MOTIF (PAM) GENERATION
#20ONCOLYTIC VIRUS SIMULTANEOUSLY EXPRESSING CD55 AND CD59
#21METHODS FOR MANUFACTURING AND USING EXTRACELLULAR VESICLES
#22NUCLEIC ACID CONSTRUCT FOR ACHIEVING MODULAR LOADING OF ENGINEERED EVS FUNCTIONAL PROTEIN AND USE OF SAID CONSTRUCT
#23GENETICALLY ENGINEERED CELLS AND USES THEREOF
#24COMPLEMENT INHIBITORS AND USES THEREOF
#25Bicistronic LAMP Constructs Comprising Immune Response Enhancing Genes and Methods of Use Thereof
#26CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE
#27EXTRACELLULAR VESICLES COMPRISING SMALL INTERFERING RNA
#28BIOMARKERS FOR CANCER THERAPEUTICS
#29MICROGLIA HAVING CAR AND USE THEREOF
#30CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#31ENGINEERED CD47 PROTEINS AND USES THEREOF
#32ANTIGENS FOR CANCER IMMUNOTHERAPY
#33DISCERNIBLE CELL SURFACE PROTEIN VARIANTS FOR USE IN CELL THERAPY
#34EXPRESSION OF NOVEL CELL TAGS
#35HUMANIZED CD1a TARGETING MOIETY FOR THE TREATMENT OF CD1A-POSITIVE CANCER
#36SIRPalpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF
#37CD38 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#38METHOD FOR MEASURING ACTIVITY OR CONCENTRATION OF ALKALINE PHOSPHATASE CONTAINED IN EXTRACELLULAR VESICLE IN SAMPLE, POLYPEPTIDE MOLECULE, METHOD FOR PRODUCING THE SAME, AND CALIBRATOR
#39ENGINEERED SWITCHES FOR IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF
#40ENHANCED ANTIGEN PRESENTING ABILITY OF CAR T CELLS BY CO-INTRODUCTION OF COSTIMULATORY MOLECULES
#41COMPOSITIONS AND METHODS FOR MEDIATING EPITOPE ENGINEERING
#42ISOLATION OF ANTI-INFLAMMATORY NEUTROPHIL OR MONOCYTE SUBSET AND USE IN TREATING CARDIOVASCULAR DISEASES
#43MULTIVALENT PARTICLES COMPOSITIONS AND METHODS OF USE
#44SYNTHETIC PATHWAY ACTIVATORS
#45POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY
#46METHODS OF TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS
#47PLASMID ENCODING AN INSULIN PEPTIDE AND Fc FUSION PROTEIN
#48PLASMID ENCODING A NGF AND Fc FUSION PROTEIN
#49PLASMID ENCODING A TLR3 AND Fc FUSION PROTEIN
#50PLASMID ENCODING A DNAse I AND Fc FUSION PROTEIN
#51PLASMID ENCODING A TLR9 AND Fc FUSION PROTEIN
#52MUTANT CD24 PROTEINS AND USES THEREOF FOR PROPHYLAXIS AND TREATMENT OF CANCER
#53CD1D-RESTRICTED NKT CELLS AS A PLATFORM FOR OFF-THE-SHELF CANCER IMMUNOTHERAPY
#54COMPLEMENT-INHIBITING HYBRID PROTEIN
#55METHODS FOR TREATING EYE DISEASE
#56FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE
#57METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#58FUSION PROTEIN FOR INDUCING IMMUNE RESPONSE AND TREATING CANCER
#59NATURAL KILLER CELLS EXPRESSING DUAL-TARGETING CHIMERIC ANTIGEN RECEPTORS FOR CD19 AND CD22, PRODUCTION METHOD AND USES THEREOF
#60PDL1 PEPTIDES FOR USE IN CANCER VACCINES
#61PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
#62HYPOIMMUNE BETA CELLS DIFFERENTIATED FROM PLURIPOTENT STEM CELLS AND RELATED USES AND METHODS
#63THERAPEUTIC MINIPROTEIN MIMICS AND A PROCESS OF PRODUCING THE SAME
#64UNIVERSAL CELL AND METHOD FOR PREPARING SAME
#65PATHOGEN-RESISTANT ANIMALS HAVING MODIFIED CD163 GENES
#66GENETICALLY ENGINEERED T CELL FOR CELL THERAPY
#67Novel formats of anti-CD28/sPD-1 fusion constructs
#68DUAL CHECKPOINT INHIBITORS AND METHODS OF USING THE SAME
#69SYNTHETIC PLATELETS
#70MULTIPLEXED-TARGETED ADENOVIRUS VECTORS AND THEIR USE
#71PD-L1-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELL COMPRISING SAME
#72GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
#73REGULATORY T CELLS WITH CHIMERIC ANTIGEN RECEPTOR TARGETING CO-STIMULATORY MOLECULES TO PREVENT AND/OR TREAT INFLAMMATORY CONDITIONS
#74COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES
#75SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
#76ARTIFICIAL SYNAPSES
#77ANTI-CD19 AND ANTI-CD79B CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
#78PROTEINASE 3 (PR3) CHIMERIC AUTOANTIBODY RECEPTOR T CELLS AND RELATED METHODS AND USES
#79BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19
#80NUCLEIC ACID CONSTRUCTS FOR EXPRESSING POLYPEPTIDES IN CELLS
#81GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC NKP46
#82ARGINASE BEARING VESICLE COMPOSITION AND METHOD OF USE
#83GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY TO REDUCE INSTANT BLOOD MEDIATED INFLAMMATORY REACTIONS
#84RECOMBINANT HUMAN CD5L PROTEIN, ACTIVE FRAGMENTS OR PEPTIDES DERIVED THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT HUMAN CD5L PROTEIN, ACTIVE FRAGMENTS OR PEPTIDES DERIVED THEREOF FOR THE TREATMENT OF ACUTE INFECTIOUS DISEASES,INFLAMMATORY DISEASES AND SEPSIS
#85ENGINEERED PD-1 VARIANTS AND METHODS OF USE THEREOF
#86LAMP Constructs
#87IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOF
#88CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#89ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
#90METHODS AND PHARMACEUTICAL COMPOSITION FOR TREATING THROMBOTIC DISORDERS
#91Genetic Modifications for Xenotransplantation
#92NKG2D-FC FOR IMMUNOTHERAPY
#93CHIMERIC BAIT RECEPTORS AND USES THEREOF
#94COMPOSITIONS AND METHODS FOR MODULATING LAIR SIGNAL TRANSDUCTION
#95CHIMERIC CD40 POLYPEPTIDES AND METHODS OF USE IN IMMUNOTHERAPY
#96METHODS OF TREATING AGE-RELATED AND INFLAMMATORY DISEASES
#97ANTI-GLYCO-LAMP1 ANTIBODIES AND THEIR USES
#98INTERLEUKIN-18 VARIANTS AND METHODS OF USE
#99METHODS AND COMPOSITIONS FOR NATURAL KILLER CELLS
#100LAIR-2 Compositions and Methods
#101CHIMERIC SWITCH RECEPTORS IN NK CELLS
#102TARGETED VESICLE COMPOSITIONS AND METHODS
#103USE OF SEMAPHORIN-4D ANTIBODIES IN COMBINATION WITH AN IMMUNE MODULATING THERAPY TO INHIBIT TUMOR GROWTH AND METASTASIS
#104SIRPALPHA SWITCH RECEPTORS
#105SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
#106KIDNEY TARGETED IMMUNOTOLERANCE
#107FUSION PROTEIN COMPRISING SIRPa MUTANT
#108PREPARATION OF ENGINEERED MYELOID CELLS
#109TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
#110TARGETING APOE ENHANCES T-CELL KILLING IN CANCER IMMUNOTHERAPY
#111EXOSOMES FOR TARGET SPECIFIC DELIVERY AND METHODS FOR PREPARING AND DELIVERING THE SAME
#112ENGINEERED IMMUNE CELLS AND METHODS FOR USE
#113Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#114GPI ANCHORED PROTEINS AND EXTRACELLULAR VESICLES COMPRISING THEM
#115CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
#116Novel Recombinant Cell Surface Markers
#117FUSION PROTEINS COMPRISING 071 CORE PEPTIDE AND USE THEREOF
#118Nanoparticles Having Molecules That Bind or Block PD-L1 and Uses In Treating Cancer
#119COMPOSITIONS, KITS AND METHODS FOR TREATMENT OF COMPLEMENT-RELATED DISORDERS
#120APOLIPOPROTEIN FUSION PROTEINS FOR CELL-SPECIFIC IMMUNE REGULATION
#121Bi-Functional Fusion Proteins to Complement Pathways and Method of Inhibiting Bone Resorption
#122GENETICALLY MODIFIED MOUSE THAT EXPRESSES HUMANIZED PD1 AND PD-L1 PROTEINS
#123PLASMID PLATFORM FOR STABLE EXPRESSION AND DELIVERY OF BIOMOLECULES
#124CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELLS THAT BIND BCMA
#125COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY
#126BINDING DOMAIN
#127METHODS OF MAKING AND USING EXTRACELLULAR DOMAIN-BASED CHIMERIC PROTEINS
#128COMPOSITIONS AND METHODS FOR CD34 GENE MODIFICATION
#129Therapeutic Anti-CD9 Antibody
#130GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY
#131METHOD FOR MODIFYING CELL
#132CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY PLATFORM
#133MODIFIED IMMUNE CELLS EXPRESSING TLR RECEPTORS
#134SYNTHETIC IMMUNO-SUPPRESSIVE CELLS AND METHODS OF USE THEREOF
#135INTRACELLULAR ANTIBODY AND PREPARATION METHOD AND USE THEREOF
#136CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF
#137TARGETED EXTRACELLULAR VESICLES COMPRISING MEMBRANE PROTEINS WITH ENGINEERED GLYCOSYLATION SITES
#138Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
#139NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME
#140TRUNCATED INFLUENZA NEURAMINIDASE AND METHODS OF USING THE SAME
#141MonoMac-1 Cells Expressing CD16 and CD163
#142COMPOSITIONS AND METHODS COMPRISING CAR T CELLS COMPRISING PRDM1 AND/OR NR4A3 KNOCKOUT
#143INTERLEUKIN-18 VARIANTS AND METHODS OF USE
#144TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
#145RODENT ANMALS EXPRESSING HUMAN CR1
#146Generation and Utility of B Cell Subsets for Treatment of Chronic Obstructive Pulmonary Disease
#147MANIPULATED IMMUNOREGULATORY ELEMENT AND IMMUNITY ALTERED THEREBY
#148CAR T CELLS THAT TARGET B-CELL ANTIGENS
#149CHIMERIC ANTIGEN RECEPTORS, COMPOSITIONS, AND METHODS
#150A CROSS-HYBRID FC-FUSION POLYPEPTIDE TARGETING PD-L1 AND METHODS AND USES RELATED THERETO
#151MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE SAME AND USES THEREOF
#152Bispecific OR-gate chimeric antigen receptor responsive to CD20 and CD19
#153TCR-T CELL FOR KILLING TUMORS, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#154Retinal Disorders
#155NON-NATURAL NKG2D RECEPTORS THAT DO NOT DIRECTLY SIGNAL THE CELLS TO WHICH THEY ARE ATTACHED
#156PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS RESISTANT ANIMALS
#157TCRS SPECIFIC FOR MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF
#158RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#159PD-1 GENE-EDITED TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
#160SKIN TARGETED IMMUNOTOLERANCE
#161Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19
#162CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS
#163PROTEINS HAVING UNNATURAL AMINO ACIDS AND METHODS OF USE
#164HYPOIMMUNOGENIC RHD NEGATIVE PRIMARY T CELLS
#165BTLA Fusion Protein Agonists and Uses Thereof
#166ISOLATED PROTEIN COMPLEXES AND COMPOSITIONS AND METHODS OF USE THEREOF
#167FULLY HUMAN ANTIBODY FOR HUMAN B7H3, CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF
#168ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA
#169Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
#170TM4SF19 INHIBITOR AND USES THEREOF
#171CHIMERIC POLYPEPTIDES, NUCLEIC ACID MOLECULES, CELLS, AND RELATED METHODS
#172Exosomes for target specific delivery and methods for preparing and delivering the same
#173NKP30 RECEPTOR TARGETED THERAPEUTICS
#174CHIMERIC ANTIGEN RECEPTORS, NUCLEIC ACIDS ENCODING THE SAME, AND USES THEREOF IN TREATING CANCERS
#175ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS
#176NKG2D-IG FUSION PROTEIN FOR CANCER IMMUNOTHERAPY
#177PEPTIDE-MHC-IMMUNOGLOBULIN MULTIMERS AND METHODS OF USE THEREOF
#178TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS
#179SCAFFOLD FOR BIFUNCTIONAL MOLECULES COMPRISING PD-1 OR CD28 AND SIRP BINDING DOMAINS
#180ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
#181CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
#182NUCLEIC ACID MOLECULES ENCODING TRIF AND ADDITIONAL POLYPEPTIDES AND THEIR USE IN TREATING CANCER
#183LIMITING VIRAL INFECTION AND REPLICATION IN STEM CELLS
#184Methods to Improve the Therapeutic Index of Activated T Cells
#185METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#186CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH CD33 TARGETING AGENTS
#187MAJOR HISTOCOMPATIBILITY COMPLEX-BASED CHIMERIC RECEPTORS AND USES THEREOF FOR TREATING AUTOIMMUNE DISEASES
#188MATERIALS AND METHODS FOR TREATING CANCER
#189POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY
#190THERAPEUTIC CELL COMPOSITIONS AND METHODS FOR MANUFACTURE AND USES THEREOF
#191UNIVERSAL CAR-T CELL TARGETING GD2, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
#192ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
#193Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
#194NON-HUMAN ANIMALS HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE
#195ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA
#196TM4SF19 INHIBITOR AND USES THEREOF
#197ANTI-CD20 ANTIBODY AND USES THEREOF
#198ANTI-CD20 ANTIBODY AND USES THEREOF
#199COMPOSITIONS AND METHODS FOR INHIBITION OF ALPHAVIRUS INFECTION
#200Pathogen-resistant animals having modified CD163 genes
#201METHOD FOR MEASURING ACTIVITY OF ALKALINE PHOSPHATEASE CONTAINED IN EXTRACELLULAR VESICLE, CALIBRATOR, AND CONJUGATE
#202SIRPalpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF
#203ENGINEERED EXTRACELLULAR VESICLES AND THEIR USES
#204Improved LAMP Constructs Comprising Cancer Antigens
#205MEASUREMENT METHOD FOR ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY
#206CD91 POLYPEPTIDE FOR USE IN DETECTING HEMOPEXIN:HEME COMPLEX
#207Retroviral And Lentiviral Vectors
#208BIFUNCTIONAL PROTEIN AND USE THEREOF
#209LAMP constructs
#210ANTIMICROBIAL TARGET
#211CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE
#212CHIMERIC TARGET FACTOR RECEPTOR
#213CHIMERIC RECEPTOR CONSTRUCTS FOR NK CELLS
#214Compositions Containing Protein Loaded Exosome and Methods for Preparing and Delivering the Same
#215ONCOLYTIC VIRUS AND USES THEREOF
#216Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy
#217ENHANCEMENT OF ANTI-TUMOR PHAGOCYTOSIS
#218INDUCIBLE SIGNALLING PROTEIN
#219MODIFIED IMMUNE EFFECTOR CELL AND USE THEREOF
#220INNATE IMMUNE CELL SILENCING BY SIRP-ALPHA ENGAGER
#221Genetically Modified Immune Cells Targeting NY-ESO-1 and Methods of Use Thereof
#222EARLY POST-TRANSFECTION ISOLATION OF CELLS (EPIC) FOR BIOLOGICS PRODUCTION
#223RECOMBINANT PROTEIN TARGETING PD-1 AND TGFBETA
#224CD47 BLOCKADE AND COMBINATION THERAPIES THEREOF FOR REDUCTION OF VASCULAR INFLAMMATION
#225Synthetic platelets
#226Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
#227Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders
#228Exosome-targeted DNA vaccine
#229Modulators of notch signaling and methods of use thereof
#230Targeted neoepitope vectors and methods therefor
#231CHIMERIC SENSOR PROTEIN AND METHODS OF USE THEREOF
#232Preparation of therapeutic exosomes using membrane proteins
#233CHIMERIC ANTIGEN RECEPTOR COMPRISING NOVEL CO-STIMULATORY DOMAIN AND USE THEREOF
#234CD164 FUSION AND USES THEREOF
#235ANTI-CD20 ANTIBODY AND USES THEREOF
#236COMPOSITIONS, METHODS AND KITS FOR TREATING COMPLEMENT RELATED DISORDERS
#237VISTA AGONIST FOR TREATMENT/PREVENTION OF ISCHEMIC AND/OR REPERFUSION INJURY
#238BINDING PROTEINS COMPRISING THE EXTRACELLULAR DOMAIN OF CD39 AND METHODS OF TREATING OR PREVENTING NEUROLOGICAL DISEASES
#239Nanoparticles having molecules that bind or block PD-L1 and uses in treating cancer
#240CD16high CD57high NK-92MI Cells
#241CD155 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#242HUMAN IMMUNE CELLS GENOMICALLY MODIFIED TO EXPRESS ORTHOGONAL RECEPTORS
#243Methods and Devices For Complexing Target Entities
#244CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL
#245METHODS AND COMPOSITIONS COMPRISING PD1 CHIMERIC POLYPEPTIDES
#246HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME
#247COMBINATION THERAPY FOR TREATING COLORECTAL CANCER
#248TARGETED CYTOKINES AND METHODS OF USE THEREOF
#249ENGINEERED EXTRACELLULAR VESICLES DISPLAYING ENHANCED PHARMACOKINETICS
#250DOWNREGULATION OF MEMBRANE-BOUND PROTEINS BY RECEPTOR TAC TECHNOLOGY
#251INTERLEUKIN-18 VARIANTS AND METHODS OF USE
#252SOLUBLE CD33 FOR TREATING MYELODYSPLASTIC SYNDROMES (MDS)
#253BIOLOGICAL MACROMOLECULAR TARGET-SPECIFIC COMPLEMENT INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
#254MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#255SALMONELLA STRAIN FOR TREATING CANCER AND USE THEREOF
#256Methods and compositions for transducing lymphocytes and regulating the activity thereof
#257OX40L-JAGGED-1 CHIMERIC POLYPEPTIDES AND USES THEREOF
#258SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES
#259Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias
#260METHODS AND COMPOSITIONS FOR GENOME EDITING
#261INTERLEUKIN-18 VARIANTS AND METHODS OF USE
#262SIRPalpha-FC FUSION PROTEIN
#263ARTIFICIAL SYNAPSES
#264HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20
#265SIGNALING DOMAINS FOR CHIMERIC ANTIGEN RECEPTORS
#266EXTRACELLULAR VESICLES WITH IMPROVED HALF-LIFE
#267PERSISTENT HSV GENE DELIVERY SYSTEM
#268CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#269Chimeric inhibitor molecules of complement activation
#270T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#271SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS
#272METHODS OF TREATING SENSITIZED PATIENTS WITH HYPOIMMUNOGENIC CELLS, AND ASSOCIATED METHODS AND COMPOSITIONS
#273Exosome for stimulating T cell and pharmaceutical use thereof
#274MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF
#275REGULATORY T CELLS GENETICALLY MODIFIED FOR THE LYMPHOTOXIN ALPHA GENE AND USES THEREOF
#276METHOD FOR THE TREATMENT OF MALIGNANCIES
#277INHIBITORY CHIMERIC RECEPTOR ARCHITECTURES
#278NOVEL CO-STIMULATORY DOMAIN AND USE THEREOF
#279Gene therapy vector with minimizing recombination, recombinant retrovirus comprising the vector, and pharmaceutical composition for preventing or treating cancer comprising the recombinant retrovirus
#280ALLOREACTIVE IMMUNE CELL-DISTANCING DEVICE AND USES THEREOF FOR PROTECTING DONOR-DERIVED CELLS FROM ALLOREJECTION
#281Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#282METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#283REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY
#284MULTISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#285CELL-DERIVED VESICLES COMPRISING TARGET PROTEIN AND METHOD FOR PRODUCING SAME
#286INTERLEUKIN-18 VARIANTS AND METHODS OF USE
#287AML ANTIGENS AND USES THEREOF
#288PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS
#289FUSION PEPTIDE FOR TREATING AUTOIMMUNE DISEASE
#290CHIMERIC ANTIGEN RECEPTOR FOR TREATMENT OF CANCER
#291MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
#292Chimeric Antigen Receptor (CAR) Comprising A CD19-Binding Domain
#293PEPTIDES FOR TREATMENT OF SEPSIS AND CANCER
#294Cells expressing recombinant growth factor receptors
#295ANTIBODIES SPECIFIC FOR CD22 AND USES THEREOF
#296COMBINED CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD20 AND APPLICATIONS THEREOF
#297IMMUNE CELLS OVEREXPRESSING CELL SIGNALING REGULATORY FACTOR INTRODUCED FROM OUTSIDE AND USE THEREOF
#298VARIANT AIM
#299PRODUCTION OF EXOSOMES AND USES THEREOF
#300Methods for treating cancer using soluble forms of PSGL-1 and fusion molecules thereof